Overview

Phase 3 Safety Study for the Treatment of Presbyopia Subjects

Status:
Recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
Safety Study of the Long-Term Safety of LNZ101 in Presbyopic Subjects
Phase:
Phase 3
Details
Lead Sponsor:
LENZ Therapeutics, Inc
Collaborator:
ORA, Inc.
Treatments:
Aceclidine
Brimonidine Tartrate
Ophthalmic Solutions
Pharmaceutical Solutions